Skip to main content
Springer Nature Link
Account

Table 4 Final model-based inotuzumab ozogamicin exposure estimation

From: Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059

Cumulative AUC estimation (median [IQR], *103 ng*h/mL)

End of cycle 1

Responders

(n = 42)

Non-responders

(n = 10)

p-Value

MRD negative

(n = 33, among responders)

MRD positive

(n = 8, among responders)

p-Value

Pediatric BCP-ALL

26.1 [18.9–35.0]

10.1 [9.19–16.1]

< 0.001

26.4 [20.1–35.1]

21.8 [10.9–29.4]

0.235

  1. AUC area under the concentration–time curve, BCP-ALL B-cell precursor acute lymphoblastic leukemia, IQR interquartile range, MRD minimal residual disease
Back to article page